BMS-986213

Phase 2Biologic

Bristol-Myers Squibb

BMS-986213 is one of 3 biologic programs targeting Melanoma (Skin). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Melanoma (skin)Recruiting

Melanoma (skin)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Melanoma (skin)

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Opdualag

Bristol-Myers Squibb

Phase 2

1 3

BMS-986213

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma (skin)

NCT05704647

Q4 2028

Phase 2Active, not recruiting

Renal Cell Carcinoma, Clear Cell

NCT06708949

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT05134948·24 enrolled

Gastroesophageal Junction (GEJ) Cancers1 trial

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03662659·274 enrolled

Effectiveness1 trial

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01968109·1,482 enrolled

Renal Cell Carcinoma, Clear Cell1 trial

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06708949·52 enrolled

Melanoma (Skin)1 trial

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05704647·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for BMS-986213. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986213 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986213. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986213

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

Gastroesophageal Junction (GEJ) Cancers1 trial

Effectiveness1 trial

Renal Cell Carcinoma, Clear Cell1 trial

Melanoma (Skin)1 trial

References

Drug Info

Quick Facts

Related News